Multiple Sclerosis (MS) is a degenerative autoimmune disease affecting the central nervous system. In this disease immune cells attack the brain's myelin sheath. It is a layer surrounding nerve fibers in the brain and spinal cord that allow the brain to transmit the electrical signals that stimulate movement. A vaccine is under trail to slow down the devastating effects of multiple sclerosis. It is to be tested for the first time on U.S. patients.
PharmaFrontiers, which are manufacturing the vaccine will study the drug's effect on 100 people with MS and compare their progress with 50 MS patients who do not get the drug.
The vaccine has inactive myelin-specific T cells that are found in the immune system. The incidence of the disease is less and about 250,000 people in the United States suffer from it. PharmaFrontiers is applying for orphan-drug status for the vaccine as it is rare by dangerous. If approved it is entitled to up to seven years market.